Reyes-Prieto BM, Velázquez-Paniagua M, Prieto-Gómez B

Idioma: Español
Referencias bibliográficas: 21
Paginas: 105-109
Archivo PDF: 72.32 Kb.

RESUMEN

La melatonina, secretada por la glándula pineal participa en diversos procesos fisiológicos. A este indol, se le ha atribuido un papel importante en la regulación de procesos rítmicos y es considerado como el mejor reductor endógeno de radicales libres. Algunas enfermedades del sistema nervioso, en particular las degenerativas pueden resultar de la interacción de múltiples factores, entre ellos, el estrés oxidativo propio de la célula, mismo que puede reducirse con la aplicación de melatonina. En esta breve revisión se comenta el uso de esta hormona para reducir algunos síntomas asociados con neuropatologías. Se sugiere que el uso de melatonina debe ser estrechamente vigilado por los posibles efectos secundarios que ésta pudiera tener, particularmente, en el aparato reproductor.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Reiter RJ, Pablos MI, Agapito TT et al. Melatonin in the context of the free radicals theory of aging. Ann N Y Acad Sci 1996; 786: 362-378.

2. Arendt J, Aldhous M, Marks V. Alleviation of jet lag by melatonin: preliminary results of controlled double blind trial. Br Med J 1986; 292: 1170.

3. Yang CM, Spielman AJ, D’Ambrosio P et al. A single dose of melatonin prevents the phase delay associated with a delayed weekend sleep pattern. Sleep 2001; 24: 272-281.

4. Zhadanova IV, Wurtman RJ, Regan MM et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 2001; 86: 4727-4730.

5. Dalton EJ, Rotondi D, Levitan RD et al. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci 2000; 25: 48-55.

6. Panksepp J, Tatonin ML. The Sleep Master. An emerging role for this over-the-counter supplement in the treatment of autism. http:// www. autism.org/ MLTatonin.html [14.11.2007]

7. Zhdanova IV, Wurtman RJ, Wagstaff J. Effects of a low dose of melatonin on sleep in children with Angelman syndrome. J Pediatr Endocrinol Metab 1999; 12: 57-67.

8. Wagstaff J. Sleep problems in individuals with Angelman syndrome. 2nd World Conference of the IASO in Washington DC, USA, 2-5 July, 2003.

9. Zlokovic BV, Deane R, Sallstrom J et al. Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol 2005; 5: 78-83.

10. Cardinali DP, Brusco LI, Liberczuk C et al. The use of melatonin in Alzheimer’s disease. Neuro Endocrinol Lett 2002; 23: 20-23.

11. Stopa EG, Volicer L, Kuo-Leblanc V et al. Pathologic evaluation of the supraquiasmatic nucleus in severe dementia. J Neuropathol Exp Neurol 1999; 58: 29-39.

12. Maurizi CP. Loss of intraventricular fluid melatonin can explain the neuropathology of Alzheimer’s disease. Med Hypotheses 1997; 492: 153-158.

13. Wu YH, Feenstra MG, Zhou JN et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer´s disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab 2003; 88: 5898-5906.

14. Savaskan E, Jockers R, Ayoub M et al. The MT2 melatonin receptor subtype is present in human retina and decreases in Alzheimer’s disease. Curr Alzheimer Res 2007; 4: 47-51.

15. Brusco LI, Fainstein I, Márquez M et al. Effect of melatonin in selected populations of sleep-disturbed patients. Biol Signals Recept 1999; 8: 126-31.

16. Dexter DT, Carter CJ, Wells FR et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson‘s disease. J Neurochem 1989; 52: 381-389.

17. Acuña-Castroviejo D, Coto-Montes A, Gaia MM et al. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997; 60: 23-29.

18. Mayo JC, Sainz RM, Uría H et al. Inhibition of cell proliferation: a mechanism likely to mediate the prevention of neuronal cell death by melatonin. FASEB J 2006; 20: 156-162.

19. Benitez-King G, Ramirez-Rodriguez G, Ortiz L et al. The neuronal cytoskeleton as a potential therapeutic target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord 2004; 3: 515-533.

20. Peled N, Shorer Z, Peled E et al. Melatonin effect on seizures in children with severe neurologic deficit disorders. Epilepsia 2001; 42: 1208-10.

21. Gutiérrez RJ, Granados CF, Martínez EC et al. Chronic melatonin application modifies the cytoarchitecture of testis and decreases the sperm number in Wistar rat. Pharmacology on line 2006; 3: 422-427.